EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection

Dereje A Negatu iD, Rubén González Del Río, Mónica Cacho-Izquierdo iD, David Barros-Aguirre iD, Joël Lelievre, Joaquín Rullas, Patricia Casado, Uday S Ganapathy, Matthew D Zimmerman, Martin Gengenbacher iD, Véronique Dartois iD, Thomas Dick iD

Antimicrobial Agents and Chemotherapy · 2023

DOI: 10.1128/aac.01459-22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Dereje A Negatu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of the β-lactam tebipenem and the β-lactamase inhibitor avibactam shows potent bactericidal activity against Mycobacterium abscessus in vitro . Here, we report that the combination of the respective oral prodrugs tebipenem-pivoxil and avibactam ARX-1796 showed efficacy in a mouse model of M. abscessus lung infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusMycobacterium Infections, NontuberculousAnimalsMiceAnti-Bacterial AgentsDisease Models, AnimalLungMicrobial Sensitivity TestsCarbapenemsAzabicyclo Compounds

Stichwörter der Autor:innen

ARX-1796NTMbeta-lactambeta-lactamase inhibitornontuberculous mycobacteriatebipenem-pivoxil

Substanzen

Anti-Bacterial AgentstebipenemCarbapenemsavibactamAzabicyclo Compounds

Autor:innen und Institutionen

  • Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
  • Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia.
  • Global Health Medicines R&D, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
  • Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
  • Department of Microbiology and Immunology, Georgetown University, Washington, DC, USA.

ORCID-Profile: Dereje A Negatu, Mónica Cacho-Izquierdo, David Barros-Aguirre, Martin Gengenbacher, Véronique Dartois, Thomas Dick

Förderung

  • NIAID NIH HHS
  • HHS | National Institutes of Health

Zitieren

APA

Negatu, D. A., González Del Río, R., Cacho-Izquierdo, M., Barros-Aguirre, D., Lelievre, J., Rullas, J., Casado, P., Ganapathy, U. S., Zimmerman, M. D., Gengenbacher, M., Dartois, V., & Dick, T. (2023). Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01459-22

Vancouver

Negatu DA, González Del Río R, Cacho-Izquierdo M, Barros-Aguirre D, Lelievre J, Rullas J, et al. Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.01459-22

BibTeX
@article{Negatu2023,
  author = {Negatu, Dereje A and González Del Río, Rubén and Cacho-Izquierdo, Mónica and Barros-Aguirre, David and Lelievre, Joël and Rullas, Joaquín and Casado, Patricia and Ganapathy, Uday S and Zimmerman, Matthew D and Gengenbacher, Martin and Dartois, Véronique and Dick, Thomas},
  title = {Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  doi = {10.1128/aac.01459-22}
}
Kostenlos starten →